Nektar Therapeutics Files 8-K on Financials
Ticker: NKTR · Form: 8-K · Filed: Nov 6, 2025 · CIK: 906709
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Nektar Therapeutics dropped an 8-K on Nov 6, 2025, detailing financial results. Check it for the latest numbers.
AI Summary
Nektar Therapeutics filed an 8-K on November 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 455 Mission Bay Boulevard South, San Francisco, California.
Why It Matters
This 8-K filing provides an update on Nektar Therapeutics' financial performance and condition, which is crucial information for investors and stakeholders to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant negative news.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- November 6, 2025 (date) — Date of earliest event reported
- 455 Mission Bay Boulevard South, San Francisco, California 94158 (location) — Address of Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated November 6, 2025.
What is the principal executive office address for Nektar Therapeutics?
The principal executive offices are located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is the Commission File Number for Nektar Therapeutics?
The Commission File Number for Nektar Therapeutics is 0-24006.
What is the IRS Employer Identification Number for Nektar Therapeutics?
The IRS Employer Identification Number for Nektar Therapeutics is 94-3134940.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-11-06 16:24:36
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
Filing Documents
- ea0264261-8k_nektar.htm (8-K) — 24KB
- ea026426101ex99-1_nektar.htm (EX-99.1) — 81KB
- ex99-1_001.jpg (GRAPHIC) — 17KB
- 0001213900-25-107180.txt ( ) — 302KB
- nktr-20251106.xsd (EX-101.SCH) — 3KB
- nktr-20251106_lab.xml (EX-101.LAB) — 33KB
- nktr-20251106_pre.xml (EX-101.PRE) — 22KB
- ea0264261-8k_nektar_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Nektar Therapeutics, a Delaware corporation ("Nektar"), issued a press release (the "Press Release") announcing its financial results for the quarter ended September 30, 2025. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release titled "Nektar Therapeutics Reports Third Quarter 2025 Financial Results." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: November 6, 2025 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2